Over the last decade, the survival outcome of patients with multiple myeloma (MM) has been
substantially improved with the emergence of novel therapeutic agents, such as proteasome …

Historically, the outcomes for individuals with triple-class refractory and penta-drug refractory
multiple myeloma (MM) have been poor because of a dearth of effective treatment options …

Most patients with multiple myeloma experience disease relapse after treatment with a B-cell
maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients …

Chimeric antigen receptor T (CAR-T) cell therapy is a promising and precise targeted
therapy for cancer that has demonstrated notable potential in clinical applications. However …

Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown
unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

Multiple myeloma (MM) is the second most common hematological malignancy of plasma
cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the …

Background Some challenges still exist with single-target B-cell maturation antigen (BCMA)
chimeric antigen receptor (CAR) T-cell therapies due to variable or negative BCMA …

Multiple myeloma is a genetically complex and heterogenous malignancy with a 5-year
survival rate of approximately 60%. Despite advances in therapy, patients experience cycles …

Although chimeric antigen receptor (CAR) T cell therapy (CAR-T) has altered the treatment
landscape for relapsed/refractory B cell malignancies and multiple myeloma, only a minority …